<DOC>
	<DOC>NCT00623415</DOC>
	<brief_summary>Flupirtine, a non-opioid analgesic drug, that has been shown to have additional neuroprotective functions, is given twice daily as an oral medication in patients with relapsing remitting multiple sclerosis over a period of 12 months. Neuroprotection is assessed by magnetic resonance imaging, magnetic resonance spectroscopy, optical coherence tomography, and clinical examination.</brief_summary>
	<brief_title>Flupirtine as Oral Treatment in Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<mesh_term>Flupirtine</mesh_term>
	<criteria>Relapsingremitting MS according to the revised McDonaldCriteria (2005) EDSS ≤ 4.0 Stable treatment with Interferonβ1b for at least 6 months Sufficient birth control (PearlIndex &lt;1) Any other MScourse than RRMS Clinically relevant gastrointestinal disease Clinically relevant pulmonary, cardiological, infectious or CNSdisease Clinically relevant disease of liver or bile system, pathological value for transaminases, gammaGT or bilirubin. Hepatitis (except uncomplicated hepatitis A with complete remission Clinically relevant dysfunction of kidneys (creatinine &gt;180 µmol/l) or bone marrow (HB &lt; 8.5 g/dl, WBC &lt; 2.5/nl thrombocytes &lt; 125/nl) Myasthenia gravis Oral anticoagulation (phenprocoumon) Treatment with carbamazepine or paracetamol Drug or alcohol abuse Pregnancy or lactation period Treatment at any time before or during study with complete lymphoradiation, monoclonal antibodies (e.g. antiCD4, Campath 1H, natalizumab), mitoxantrone, cyclophosphamide, cyclosporin, azathioprine Treatment within 6 months before randomization with any other immunomodulatory substance than interferonβ1b or intravenous methylprednisolone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>